RAPP Director John Maraganore Buys $249K of Stock

Director John Maraganore bought 9,411 shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) on October 22, 2026. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission.

RAPP Rapport Therapeutics, Inc.

$26.53 ▼ -5.62% year to date

1M 3M YTD

Daily close · Oct 22, 2026

Inside John Maraganore's RAPP Trade

Maraganore picked up the shares at an average price of $26.45 per share, bringing the total value of the purchase to $248,891.83. Following the open-market transaction, the director directly held 9,411 shares of the clinical-stage biotechnology company.

Other Institutional Activity in Rapport Therapeutics

Large investors adjusted their positions in the company during recent quarters. Trv Gp V, LLC reduced its holdings by 854,814 shares, ending the period with 6,280,525 shares valued at $166,622,332. Arch Venture Management, Llc kept its stake steady at 3,728,738 shares worth $98,923,421. Capital International Investors trimmed its position by 175,962 shares to hold 2,921,958 shares valued at $77,519,547. Cormorant Asset Management, LP lowered its holdings by 299,881 shares, leaving it with 2,657,521 shares worth $70,504,033. Sofinnova Investments, Inc. maintained its position unchanged, owning 1,904,408 shares valued at $50,523,945.

Rapport Therapeutics, Inc. Stock Up 5.9%

RAPP shares recently traded around $26.53 on October 22, 2026, matching the stock's closing price on the day of Maraganore's trade. The stock sits below its 50-day moving average of $39.90 and under its 200-day moving average of $35.75. The company has a market capitalization of roughly $1.27 billion and a beta of 1.219.

Recent Earnings

Rapport Therapeutics reported trailing twelve-month revenue of $20.0 million and an EPS of -$3.03. The firm carries a return on equity of -40.0% and has a current ratio of 15.721 alongside a quick ratio of 15.352. Investors look toward the company's upcoming earnings report on November 5, 2026, for further operational updates.

Insider Buying and Selling at Rapport Therapeutics, Inc.

Insider activity at the firm has included multiple transactions in recent weeks. Chief Operating Officer Cheryl Gault disposed of 10,000 shares on September 30, 2026, in a transaction valued at $331,856. Chief Executive Officer Abraham N. Ceesay sold 4,522 shares on October 7, 2026, for about $143,273. Chief Financial Officer Troy A. Ignelzi bought 5,500 shares on October 21, 2026, at an average price of $26.10, totaling $143,550 and lifting his stake to 15,500 shares.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the trade. HC Wainwright & Co. reiterated a buy rating with a $66.00 price target on October 20, 2026. BTIG maintained a buy rating on October 20, 2026, raising its target from $75.00 to $89.00. Jones Trading maintained a buy rating on October 21, 2026, lifting its target from $50.00 to $82.00. Wells Fargo maintained an overweight rating on October 21, 2026, adjusting its target from $51.00 to $50.00. Guggenheim maintained a buy rating on October 21, 2026, raising its target from $65.00 to $70.00. The stock currently holds a consensus strong buy rating and an average price target of $69.46 from 15 analyst opinions.

About Rapport Therapeutics

Rapport Therapeutics is a Boston-based clinical-stage biopharmaceutical company focused on discovering and developing small molecule medicines for central nervous system disorders. Insider purchases by directors and executives draw attention from market watchers as the company advances its clinical pipeline.

Bottom Line

Director John Maraganore's purchase adds to recent insider transactions at Rapport Therapeutics. Market participants will monitor the company's next earnings release on November 5, 2026, for progress on its clinical programs.